3 unknown, 1 active not recruiting, 1 completed, 1 recruiting. 6 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Unknown 3, Active not recruiting 1, Completed 1, Recruiting 1 |
| Phase 3 | 2 | Completed 1, Unknown 1 |
Follow Pathological Complete Response: new trials by email Literature Review of Pathological Complete Response trials Research Report on Pathological Complete Response
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant Immunochemotherapy and Chemoradiotherapy Followed by Surgery for Advanced Esophageal Squamous Cell Carcinoma Tislelizumab, Paclitaxel, Cisplatin - ESCC, Total Neoadjuvant Treatment | Phase 2 | Recruiting | National Taiwan University Hospital | 50 | 2025-07-23 | 2026-01-27 |
| Clinical Study on the Safety and Relationship of Sintilimab Combined With Chemotherapy in Neoadjuvant Treatment of Locally Advanced Rectal Adenocarcinoma Sintilimab combined with XELOX - Pathological Complete Response, Rectal Cancer | Phase 2 | Active not recruiting | The First Affiliated Hospital of Anhui Medical University | 50 | 2022-06-01 | 2025-11-21 |
| Efficacy and Safety of Combinition of Camrelizumab in Second-line Neoadjuvant Chemotherapy and Adjuvant Therapy Camrelizumab with vinorelbine and cisplatin - HER2-negative Breast Cancer, Neoadjuvant Therapy | Phase 2 | Unknown | Peking University First Hospital | 30 | 2021-11-20 | 2022-10-18 |
| Effect of Concurrent Capecitabine-based Long-term Radiotherapy Followed by XELOX Plus TME in Patients With High Risk Rectal Cancer: a Multi-centers, Randomized Controlled, Open-Label Trial concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME, concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX - Rectal Cancer, Pathological Complete Response | Phase 2 | Unknown | Peking University People's Hospital | 244 | 2018-01-31 | 2023-03-22 |
| Pathological Complete Response Rate in Locally Advanced Breast Cancer With FEC, EC-T, or TC as Neoadjuvant Chemotherapy Epirubicin, Fluorouracil, Docetaxel - Breast Cancer, Pathological Complete Response | Phase 2 / Phase 3 | Unknown | Zhiyong Yu | 200 | 2017-11-27 | 2017-11-21 |
| DIetary REstriction as an Adjunct to Neoadjuvant ChemoTherapy for HER2 Negative Breast Cancer Fasting mimicking diet - Fasting Mimicking Diet, Breast Cancer | Phase 2 / Phase 3 | Completed | Leiden University Medical Center | 131 | 2014-02-01 | 2019-10-24 |
Breast Neoplasms (2) · Rectal Neoplasms (2)
Neoplasms (4) · Neoplasms by Site (4) · Breast Diseases (2) · Colorectal Neoplasms (2) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Gastrointestinal Diseases (2) · Gastrointestinal Neoplasms (2) · Intestinal Diseases (2) · Intestinal Neoplasms (2) · Rectal Diseases (2) · Skin Diseases (2) · Skin and Connective Tissue Diseases (2)
Cisplatin (2) · Chemoradiotherapy (1) · Cyclophosphamide (1) · Docetaxel (1) · Doxorubicin (1) · Epirubicin (1) · Fluorouracil (1) · Paclitaxel (1) · Vinorelbine (1) · XELOX (1) · camrelizumab (1) · tislelizumab (1)
Leiden University Medical Center (1) · National Taiwan University Hospital (1) · Peking University First Hospital (1) · Peking University People's Hospital (1) · The First Affiliated Hospital of Anhui Medical University (1) · Zhiyong Yu (1)
China (3) · Netherlands (1) · Taiwan (1)
Hanno Pijl, MD PhD (1) · Judith R Kroep, MD, PhD (1) · Xiaoshan Cao, MD (1) · Zhiyong Yu, PhD (1)
PMID 20106720, PMID 21066983, PMID 21596621, PMID 21747092, PMID 22367706, PMID 22529255, PMID 26187751, PMID 26189067, PMID 27254838, PMID 27480145, PMID 32576828, PMID 33179154